David Zanoni
Momentum, growth at reasonable price, long-term horizon

New Sources Of Revenue And Profitability Are In The Future For Dyax

Executive summary:

  • Dyax's patented technology helps leading pharmaceutical companies to develop drugs efficiently at lower costs.
  • Profitability is on the horizon due to new potential revenue sources from its partners.
  • The balance sheet has improved and cash burn is being reduced.
  • The company should be a good long-term investment as new drugs in the pipeline become approved.


Biotech companies are intriguing as possible investments not only for their potential stock gains, but also for their contributions to help improve and save the lives of individuals. One company that looks promising for the long-term is Dyax Corporation (NASDAQ:DYAX). The company utilizes the technology known as phage display, which allows for a rapid identification of drug candidates by identifying...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details